Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?
Journal Title: Journal of Cancer Research & Therapy - Year 2017, Vol 5, Issue 7
Abstract
Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell lung cancer (NSCLC). The aim of this analysis was to evaluate whether skin rash during treatment (as a biomarker) in a preoperative setting was related to response and survival. Methods: This study was designed as an open-label phase II trial (also known as M06NEL). Patients received preoperative erlotinib (Tarceva) 150 mg once daily for 3 weeks. Skin toxicity during treatment was analysed in relation to metabolic and histopathological response, overall survival (OS) and progression-free survival (PFS). Results: In total 59 patients (25 male, 34 female) were eligible for analysis. In 39 patients (66%) skin toxicity occurred. According to National Cancer Institute Common Toxicity Criteria (NCICTC), Grade 1 toxicity was seen in 15 patients (25%), Grade 2 in 19 patients (32%) and Grade 3 in five patients (8%). None of the patients showed skin toxicity Grade 4 and 5. The median follow up was 74 months. Thirty-six patients (61%) were alive at time of analysis. Twenty-seven patients (46%) showed disease progression during follow up. Hazard ratios (HR) indicated lower risk of death (HR = 0.66, 95%CI: 0.29 - 1.50) and progression (HR = 0.64, 0.30 - 1.36), although in this small group results were not significant. Skin rash did not adequately predict response. Conclusions: In this neoadjuvant setting with limited treatment time in patients with early stage NSCLC, skin rash was not associated with response and survival and cannot be used as an early biomarker.
Authors and Affiliations
M. H. van Gool, J. A. Burgers, Sikorska 1, E. E. Schaake, T. S. Aukema, H. M. Klomp
Keywords
Related Articles
- EP ID EP539148
- DOI 10.14312/2052-4994.2017-9
- Views 62
- Downloads 0
Inhibition of glycolysis and growth of colon cancer cells by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) in combination with butyrate, 2-deoxy glucose, 3-bromopyruvate or biguanides
Introduction: Glycolysis shows a positive correlation with growth of human colon cancer cells. PFKFB3 is an important enzyme regulating glycolysis in many tumor cells and presents a target for cancer chemotherapy. We stu...
An anaplastic cardiac large cell lymphoma: A case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin’s lymphoma from the Czech Lymphoma Study Group (CLSG) database
We report a rare case of anaplastic large cell ALK+ lymphoma (ALCL) with initial asymptomatic cardiac involvement. A 59-year-old male with infiltration of the right ventricular wall underwent standard combined chemothera...
Economic evaluation of monoclonal antibody in the management of colorectal cancer
Objective: This study aims to determine the cost of colorectal cancer (CRC) management and compare the cost effectiveness of cetuximab and bevacizumab in the management of CRC. Method: This economic evaluation study from...
Current trends and controversies in the management of patients with splenic flexure tumours
Aim: There exists a variation in practice in the management of tumours around the splenic flexure. We aim to determine the current opinion regarding the management of these tumours. Methods: An anonymised 10-part online...
Structural imaging of the pancreas in rat using micro-CT: application to a non-invasivelongitudinal evaluation of pancreatic ductal carcinoma monitoring
The aim of the study was to evaluate the feasibility of a longitudinal non-invasive monitoring of rat pancreatic ductal adenocarcinoma (PDAC) using microCTscans (μCT). The identification of the pancreatic gland on (μCT)...